433
Views
6
CrossRef citations to date
0
Altmetric
Reviews

Targeting the dopamine receptor in schizophrenia: investigational drugs in Phase III trials

, MBBS MD & , MD PhD FRCPC

Keep up to date with the latest research on this topic with citation updates for this article.

Read on this site (2)

Pedro Barroso-Chinea, Diego Luis-Ravelo, Felipe Fumagallo-Reading, Javier Castro-Hernandez, Josmar Salas-Hernandez, Julia Rodriguez-Nuñez, Alejandro Febles-Casquero, Ignacio Cruz-Muros, Domingo Afonso-Oramas, Pedro Abreu-Gonzalez, Rosario Moratalla, Mark J. Millan & Tomas Gonzalez-Hernandez. (2020) DRD3 (dopamine receptor D3) but not DRD2 activates autophagy through MTORC1 inhibition preserving protein synthesis. Autophagy 16:7, pages 1279-1295.
Read now
Sheng-Min Wang, Changsu Han, Soo-Jung Lee, Tae-Youn Jun, Ashwin A. Patkar, Prakash S. Masand & Chi-Un Pae. (2017) Investigational dopamine antagonists for the treatment of schizophrenia. Expert Opinion on Investigational Drugs 26:6, pages 687-698.
Read now

Articles from other publishers (4)

Haley Maria Dourron, Camilla Strauss & Peter S. Hendricks. (2022) Self-Entropic Broadening Theory: Toward a New Understanding of Self and Behavior Change Informed by Psychedelics and Psychosis. Pharmacological Reviews 74:4, pages 984-1029.
Crossref
Charles D. Ciccone. 2020. Guccione's Geriatric Physical Therapy. Guccione's Geriatric Physical Therapy 102 136 .
Janis C. Weeks, William M. Roberts, Caitlyn Leasure, Brian M. Suzuki, Kristin J. Robinson, Heather Currey, Phurpa Wangchuk, Ramon M. Eichenberger, Aleen D. Saxton, Thomas D. Bird, Brian C. Kraemer, Alex Loukas, John M. Hawdon, Conor R. Caffrey & Nicole F. Liachko. (2018) Sertraline, Paroxetine, and Chlorpromazine Are Rapidly Acting Anthelmintic Drugs Capable of Clinical Repurposing. Scientific Reports 8:1.
Crossref
Giuseppe Di Giovanni & Philippe De Deurwaerdère. (2016) New therapeutic opportunities for 5-HT2C receptor ligands in neuropsychiatric disorders. Pharmacology & Therapeutics 157, pages 125-162.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.